CoChat

Repurposing available drugs for neurodevelopmental disorders: The fragile X experience

Open access
Tranfaglia, Michael R., Thibodeaux, Clare, Mason, Daniel J., Brown, David, Roberts, Ian, Smith, Richard, Guilliams, Tim, Cogram, Patricia · 2019 · Neuropharmacology
Cited by 39

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Many available drugs have been repurposed as treatments for neurodevelopmental disorders. In the specific case of fragile X syndrome, many clinical trials of available drugs have been conducted with the goal of disease modification. In some cases, detailed understanding of basic disease mechanisms has guided the choice of drugs for clinical trials, and several notable successes in fragile X clinical trials have led to common use of drugs such as minocycline in routine medical practice. Newer technologies like Disease‐Gene Expression Matching (DGEM) may allow for more rapid identification of promising repurposing candidates. A DGEM study predicted that sulindac could be therapeutic for fragile X, and subsequent preclinical validation studies have shown promising results. The use of combinations of available drugs and nutraceuticals has the potential to greatly expand the options for repurposing, and may even be a viable business strategy. This article is part of the Special Issue entitled ‘Drug Repurposing: old molecules, new ways to fast track drug discovery and development for CNS disorders’. HighlightsThe history of drug repurposing efforts for fragile X is reviewed.Results of an original repurposing study using transcriptomic data is presented.Original results from preclinical validation of repurposing predictions are presented.Sulindac is identified as a promising repurposing candidate for fragile X.Metformin is confirmed as another promising candidate drug.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2018.05.004

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 39

Metadata

Authors
Tranfaglia, M. R., Thibodeaux, C., Mason, D. J., Brown, D., Roberts, I., Smith, R., Guilliams, T., & Cogram, P.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2019-03
Volume
147
Pages
74-86
ISSN
0028-3908 (ISSN-L)
OpenAlex
W2800642779
Cited by
39
References
29
FWCI
3.05
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Repurposing available drugs for neurodevelopmental disorders: The fragile X experience. https://app.cochat.ai/papers/10.1016/j.neuropharm.2018.05.004
The paper
Tranfaglia, M. R., Thibodeaux, C., Mason, D. J., Brown, D., Roberts, I., Smith, R., Guilliams, T., & Cogram, P. (2019). Repurposing available drugs for neurodevelopmental disorders: The fragile X experience. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2018.05.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.